Samjin raises sales target over 3 medicines

Published: 2009-06-22 06:56:00

Updated: 2009-06-22 06:56:00

Samjin Pharm has raised its sales target of three drugs, such as antiplatelet agent ‘Platless (clopidogrel)’, antihypertesive ‘ARB’ and anti-dementia drug, in the domestic market for this year as these products will be on a major leap forward as the nation is rapidly growing into an aging society...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK